Please select the option that best describes you:

Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?   

What is your general philosophy when discontinuing and/or switching chemotherapy in the recurrent setting? 



Answer from: at Academic Institution
Sign in or Register to read more

Answer from: at Community Practice
Sign in or Register to read more